EUVIMEDEUVIMED entdecken
Crossref

Immunostimulation During and After R-CHOP Therapy for B-Cell Lymphoma

Journal of Clinical & Experimental Immunology · 2016

DOI: 10.33140/jcei.01.01.07 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical & Experimental Immunology, 2016.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds: Many studies show an immune imbalance in the tumor environment; some reports show that the T helper 1 (Th1)/ T helper 2 (Th2) ratio, the number of regulatory T-cells (Treg cells) or CD8+T-cells, and the CD8+Tcell/Treg cell ratio are associated with tumor suppression and expansion. Additionally, chemotherapy was reported to affect the immunity of patients with malignancy. Patients and Methods: Using flow cytometry we measured peripheral blood lymphocytes including non T-cells, as well as T-cell subsets such as CD3+T-cells, CD4+T-cells, CD8+T-cells, Treg cells, Th1 cells and Th2 cells before treatment, at the fourth cycle, and at 1, 3, 6 and 12 months after treatment in 21 patients with B-cell lymphoma receiving R-CHOP therapy. We also analyzed the changes in three immune indexes that reflect anti-tumor immunity (the CD4/CD8 ratio, the CD8/Treg ratio and the Th1/Th2 ratio). Results: Compared to pre-treatment there were significant decreases in the CD4/CD8 ratio between 1 month and 12 months after treatment (p

Zitieren

APA

(2016). Immunostimulation During and After R-CHOP Therapy for B-Cell Lymphoma. Journal of Clinical & Experimental Immunology. https://doi.org/10.33140/jcei.01.01.07

Vancouver

Immunostimulation During and After R-CHOP Therapy for B-Cell Lymphoma. Journal of Clinical & Experimental Immunology. 2016. doi:10.33140/jcei.01.01.07

BibTeX
@article{euvimed2016,
  title = {Immunostimulation During and After R-CHOP Therapy for B-Cell Lymphoma},
  journal = {Journal of Clinical & Experimental Immunology},
  year = {2016},
  doi = {10.33140/jcei.01.01.07}
}
Kostenlos starten →